Inflammation

Latest News

Patient experiencing a bronchiectasis exacerbation | Image Credit: Jo Panuwat D - stock.adobe.com
Highly Symptomatic Patients With Bronchiectasis Face Increased Exacerbation Risk

September 11th 2025

Patients with bronchiectasis who are highly symptomatic face an increased risk of future exacerbations, suggesting symptoms should guide prevention strategies.

Older person eating healthy meal | Image Credit: Png - Video - Photo - stock.adobe.com
Low GNRI Score Associated With Higher All-Cause, Cardiovascular Mortality Rates in Older Adults With Osteoarthritis

August 15th 2025

The authors noted their research should be seen as a first step into the exploration of transcriptomics in the 2 diseases. | Image credit: Evrymmnt - stock.adobe.com
Study Identifies SSc, SLE Gene Expression Signatures

August 14th 2025

FDA approved | Image Credit: Pawel - stock.adobe.com
Brensocatib Becomes First FDA-Approved Therapy for Bronchiectasis

August 12th 2025

Depiction of inflammation | Image Credit: picture-waterfall - stock.adobe.com
Higher Oxidative Balance Score Linked to Lower Systemic Inflammation, Study Finds

August 5th 2025

Continuing Medical Education
View All
September 16th 2025

Advancing Targeted Therapies Aimed at Smoldering Disease in Multiple Sclerosis

1.0 Credit / Immunology, Neurology
September 16th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
September 16th 2025

From Treatment to Prevention: Navigating the Expanding Hereditary Angioedema Treatment Landscape

August 13, 2025 | 1:00 PM & 8:00 PM EDT
September 16th 2025

Innovations in Hidradenitis Suppurativa Treatment: Navigating the Evolving Landscape for Managed Care Professionals

August 19, 2025 | 1:00 PM & 8:00 PM ET
September 16th 2025

Optimizing Outcomes in Myasthenia Gravis: Therapeutic Advances and Value-Based Care Models

August 21, 2025 | 1:00 PM ET & 8:00 PM ET
September 16th 2025

Managed Care Insights on the Advances in the Eosinophilic Esophagitis Treatment Landscape

1.0 Credit / Gastroenterology, Immunology, Rare Diseases
September 16th 2025

Managing Patients With COPD: Evidence-Based Care and Optimizing Value of New and Emerging Targeted Therapies

1.0 Credit / Immunology, Pulmonology/Respiratory
September 16th 2025

Managed Care Approaches to Individualize Treatment of Hereditary Angioedema

1.0 Credit / Immunology
September 16th 2025

From Strict Avoidance to Tailored Therapies: Transforming Food Allergy Care

1.5 Credits / Allergy, Immunology
September 16th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health
September 16th 2025

Leveraging Biologics and Immunotherapies in the Management of Food Allergies

1.5 Credits / Immunology, Allergy
September 16th 2025

Reflecting on the Real-World Use of Biologic Therapy in Asthma Management

1.5 Credits / Immunology, Pulmonology
September 16th 2025

Targeting Chronic Rhinosinusitis With Nasal Polyps With Biologics: Optimizing Outcomes and Reducing Health Care Burden

1.5 Credits / Immunology
September 16th 2025

Emerging Treatment Options for Inflammatory Bowel Disease: A Focus on IL-23 Pathway Inhibition

1.5 Credits / Gastroenterology, Immunology
September 16th 2025

Innovations in Inflammatory Bowel Disease Therapy: How IL-23 Inhibitors Are Shaping Treatment and Managed Care Approaches

1.5 Credits / Gastroenterology, Immunology
September 16th 2025

The Expanding Therapeutic Landscape in IgA Nephropathy: Applying Evidence-Based Strategies and Guideline Updates for Managed Care

1.0 Credit / Immunology, Nephrology
September 16th 2025

The Expanding Therapeutic Landscape in IgA Nephropathy: A Case-Based Exploration of Optimized Patient Outcomes

1.0 Credit / Immunology, Nephrology

More News

Review Examines Use of Biologics in Atopic, Inflammatory Diseases
January 16th 2021

Review Examines Use of Biologics in Atopic, Inflammatory Diseases

Skylar Jeremias
A recent review explores the use of biologics in atopic and inflammatory conditions as well as lingering research gaps.
Study Compares Mepolizumab, Benralizumab for Eosinophilic Asthma
January 15th 2021

Study Compares Mepolizumab, Benralizumab for Eosinophilic Asthma

Gianna Melillo
Mepolizumab and benralizumab are both potent targets of the interlukin-5 pathway with the ability to significantly reduce eosinophil counts, according to new research published in Allergy, Asthma & Clinical Immunology.
Review Probes Role of Eosinophils in Chronic Rhinosinusitis With, Without Polyps
January 8th 2021

Review Probes Role of Eosinophils in Chronic Rhinosinusitis With, Without Polyps

Jaime Rosenberg
A review explored the potential role of eosinophils and their mediators in the pathophysiology of chronic rhinosinusitis (CRS) subtypes.
Dr Matthew J. Zirwas: How Launch of New Biologics May Change AD Management
December 31st 2020

Dr Matthew J. Zirwas: How Launch of New Biologics May Change AD Management

Matthew J. Zirwas, MD, a dermatologist in Ohio, discusses how dermatologists may stratify patients with atopic dermatitis (AD) with the launch of new biologic treatments in 2021.
What a Review Says About Biologics for Allergic Bronchopulmonary Aspergillosis, Asthma, CF
December 27th 2020

What a Review Says About Biologics for Allergic Bronchopulmonary Aspergillosis, Asthma, CF

Jaime Rosenberg
The review of 32 studies revealed that biologic treatment tended to favor patients with allergic bronchopulmonary aspergillosis (ABPA) and asthma rather than those with cystic fibrosis (CF).
Patients With Atopic Dermatitis Report Broad Array of OOP Expenses Related to Disease
December 26th 2020

Patients With Atopic Dermatitis Report Broad Array of OOP Expenses Related to Disease

Laura Joszt, MA
In addition to significant morbidity and impaired health-related quality of life, patients with atopic dermatitis have a significant out-of-pocket (OOP) financial burden related to their disease.
Top 5 inflammation stories of 2020
December 23rd 2020

Top 5 Most-Read Inflammation Articles of 2020

Christina Mattina
This year, the most popular articles and interviews related to the role of inflammation in asthma and other conditions touched on the mechanisms of inflammation, patterns of inhaler use, and the real-world impacts of the monoclonal antibody dupilumab.
Subgroup Analysis Confirms Safety, Efficacy of Dupilumab in Chronic Rhinosinusitis With Nasal Polyps
December 19th 2020

Subgroup Analysis Confirms Safety, Efficacy of Dupilumab in Chronic Rhinosinusitis With Nasal Polyps

Laura Joszt, MA
The analysis reviewed the safety and efficacy among patients in Japan to confirm the findings of the overall study population.
David Pariser, MD
December 18th 2020

Dr David Pariser Outlines Unmet Needs in Treatment Options for Atopic Dermatitis

The treatment landscape for atopic dermatitis is beginning to change from the use of topical therapies to biologics and more, said David Pariser, MD, senior physician at Pariser Dermatology Specialists and professor at Eastern Virginia Medical School Department of Dermatology.
Older Adults Are Often Excluded From RCTs of Systemic Treatments for Atopic Dermatitis
December 17th 2020

Older Adults Are Often Excluded From RCTs of Systemic Treatments for Atopic Dermatitis

Laura Joszt, MA
Older adults are often at greater risk for adverse events from treatments, but they can also be excluded from randomized controlled trials (RCTs), making it difficult to know if findings are generalizable to this population.
Site Logo
December 11th 2020

Guideline-Informed Care Among Medicaid-Enrolled Children With Food Allergy

Madeleine K. Kanaley, BA Ashley A. Dyer, MPH Olivia R. Negris, MA Jamie L. Fierstein, PhD Christina E. Ciaccio, MD, MSc Ruchi S. Gupta, MD, MPH Lucy A. Bilaver, PhD
This article describes food allergy–related service utilization and identifies factors associated with guideline-informed care among Medicaid-enrolled US children with food allergy.
Child using inhaler
December 10th 2020

Registry for Children With Severe Asthma Shows Potential in Aiding Drug Trial Design

Skylar Jeremias
Investigators concluded that use of a new registry could aid in the recruitment of pediatric subjects with severe asthma and the design of future clinical trials for emerging biologics.
David Pariser, MD
December 10th 2020

Dr David Pariser Highlights Comorbidities and Treatments in the Pipeline for Atopic Dermatitis

The comorbidities associated with atopic dermatitis can be substantial, and the disease can have a significant burden on quality of life, but new biologics and other future treatments may help, said David Pariser, MD, senior physician at Pariser Dermatology Specialists.
David Pariser, MD
December 5th 2020

Dr David Pariser Discusses the Significant Burden of Atopic Dermatitis

The financial, physical, and social burdens of atopic dermatitis can be substantial, especially for patients who had the condition as children into adulthood, said David Pariser, MD, senior physician at Pariser Dermatology Specialists and professor at Eastern Virginia Medical School Department of Dermatology.
National Asthma Guidelines Get First Update in 13 Years
December 4th 2020

National Asthma Guidelines Get First Update in 13 Years

Laura Joszt, MA
Updated guidance in 6 key areas of asthma care focus on improving diagnosis, management, and treatment.
David Pariser, MD
November 28th 2020

Dr David Pariser Outlines Future Treatment Options of Atopic Dermatitis With Biologics and JAK Inhibitors

As the only biologic on the market, dupilumab has replaced most of the more traditional treatments for atopic dermatitis, said David Pariser, MD, senior physician at Pariser Dermatology Specialists.
Behavior Intervention Can Increase Physical Activity and Improve Asthma Control
November 25th 2020

Behavior Intervention Can Increase Physical Activity and Improve Asthma Control

Laura Joszt, MA
Patients with asthma can improve their disease control and sleep quality, while reducing depression and anxiety through a behavior change intervention aimed at increasing their physical activity.
Insurance Expansion Reduced Asthma Emergencies in New York City
November 17th 2020

Insurance Expansion Reduced Asthma Emergencies in New York City

Laura Joszt, MA
Expansion of insurance coverage due to the Affordable Care Act led to a reduction in the use of emergency services for patients with asthma in New York City.
eczema
November 15th 2020

Dupilumab Reduces Pain, Discomfort in Patients With Moderate to Severe Atopic Dermatitis

Laura Joszt, MA
Dupilumab, with or without topical corticosteroids, significantly reduced pain and discomfort in patients with moderate to severe atopic dermatitis.
Nicola Hanania, MD, MS, Baylor College of Medicine
November 11th 2020

Dr Nicola Hanania: Treatment of T2-High Asthma Is Constantly Evolving

Treatment targets include several interleukins, immunoglobulin E, and alarmins, pointed out Nicola Hanania, MD, MS, pulmonary critical care physician and director, Airway Clinical Research Center, Baylor College of Medicine, Houston.
asthma inhaler
November 8th 2020

Overuse of Reliever Inhalers Does Not Necessarily Mean Greater Health Care Utilization

Laura Joszt, MA
Overuse of reliever inhalers among adult patients with asthma is prevalent, but does not necessarily translate into higher all-cause health care utilization (HCU), according to a study published in Scientific Reports.
Anne Reihman, MD, University of Colorado
November 7th 2020

Dr Anne Reihman: Anti–IL-5 Therapies Can Be Life-Changing for Patients With Eosinophilic Asthma

Categorizing by eosinophilic/noneosinophilic subtype enables better targeted treatment, noted Anne Reihman, MD, third-year pulmonary and critical care fellow, University of Colorado, Division of Pulmonary Sciences and Critical Care Medicine.
Vitamin D supplementation
November 6th 2020

Vitamin D May Ease Symptoms of Severe Atopic Dermatitis in Children

Laura Joszt, MA
Vitamin D used as an adjuvant therapy in children with severe atopic dermatitis may improve clinical outcomes, according to a recent study.
J. Allen Meadows, MD
October 31st 2020

Dr J. Allen Meadows Discusses Adherence to Biologics for Asthma

Despite the price, adherence to biologics for asthma is usually good because of the effectiveness, said J. Allen Meadows, MD, president of the American College of Allergy, Asthma & Immunology.
Home health care
October 28th 2020

Weighing the Pros, Cons of At-Home Use of Biologics for Asthma

Laura Joszt, MA
When the first biologic to treat asthma was approved by the FDA in 2003, it needed to be administered subcutaneously in the physician’s office. Now, there are 3 options available for at-home use: mepolizumab, benralizumab, and dupilumab.
J. Allen Meadows, MD, president, American College of Allergy, Asthma & Immunology
October 22nd 2020

Dr J. Allen Meadows on Using Shared Decision-Making to Choose Among Biologics for Asthma

There are clear differences between the biologics approved to treat asthma, and finding the right one for a patient requires shared decision-making conversations, said J. Allen Meadows, MD.
Teen girl being comforted
October 19th 2020

Addressing the QOL Impact and Disease Burden on the Families of Adolescents With Atopic Dermatitis

Laura Joszt, MA
Atopic dermatitis (AD) has a negative impact on quality of life, and the burden of this disease in adolescents and their parents should be taken into account as part of the management of AD.
J. Allen Meadows, MD, American College of Allergy, Asthma & Immunology
October 14th 2020

Dr J. Allen Meadows on Making the Decision to Put a Patient With Asthma on a Biologic

Patients with severe asthma are good candidates for biologics, but choosing which biologic requires a shared decision-making conversation, said J. Allen Meadows, MD, president of the American College of Allergy, Asthma & Immunology.
child with asthma inhaler
October 14th 2020

Phase 3 Trial Finds Dupilumab Significantly Reduced Severe Asthma Attacks in Children

Laura Joszt, MA
Improvements in lung function occurred as early as 2 weeks after the first dose of treatment.
J. Allen Meadows, MD, president of the American College of Allergy, Asthma & Immunology
October 10th 2020

Dr J. Allen Meadows Outlines New Long-term Safety, Efficacy Data for Dupilumab in Asthma

New data on the long-term efficacy and safety of dupilumab are very reassuring to patients with asthma, explained J. Allen Meadows, MD, president of the American College of Allergy, Asthma & Immunology.
<1
...
6789101112>

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo